Play Some Defense
Usually, when the market is doing well, stocks aren’t affected much by the news of the day. That’s not to say individual stocks don’t get pushed around, but for the market as a whole, worrisome headline news usually goes the way water...
Read More
Passing T-Storms—or Something More?
On this page of the last issue, we wrote “we think the near-term is a toss-up, at least when it comes to individual growth stocks— earnings season is always tricky, and let’s face it, many leaders have had great runs the...
Read More
Mostly Sunny—with Possible T-Storms Along the Way
Ever since January 9, when the 2-to-1 Blastoff Indicator gave a rare buy signal just two weeks after the market’s major bottom, our greatest conviction has been that the overall market had likely entered a new bull that...
Read More
The Odds Still Favor Higher Prices Ahead
It was a solid first half of 2019 for most major indexes and growth stocks. Despite a few knocks upside the head last week, our Model Portfolio finished June up nearly 22% on the year. In fact, the...
Read More
Still Going According to Script
Back on January 31, we wrote that the market was basically following a perfect Hollywood-type script for a major market bottom—you had a three-month bear phase that produced huge oversold readings and massive pessimism near the low, followed by turn...
Read More
Pieces are in Place
We’re about five weeks into this market correction, and it’s been a pretty nasty one when looking at the major indexes—from high to low, the S&P 500 has fallen as much as 7.6% and the Nasdaq by 10.8%, with small- mid-cap...
Read More
Time Likely Needed
In The Perfect Speculator (written by Brad Koteshwar), fictional trader Boyd Hunt said, “Everything in the market takes time. Learning takes time. Making gains takes time. Even losing big takes time because the market will occasionally offer small crumbs to remove (We...
Read More
The biotech sector is in full recovery mode, and the best biotech stocks are still on sale. Here's where you can find them.
Read More
I have no idea if the biotech sector is near a bottom, but based on history, it would seem that we’re within 10% or so of that mark. The greatest risk seems to be that the binary outcome possibilities for developmental-stage biotech (either...
Read More
Have you ever wondered how to find great biotech stocks in a sea of hopeful but high-risk medical small caps? Well, for my latest Dick Davis Digest contributor interview, I interviewed John McCamant, the editor of a top-performing investment newsletter that’s all about the...
Read More